Phathom Pharmaceuticals, Inc. — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This is a routine quarterly report (10-Q) filing for the period ending September 30, 2026, submitted October 29, 2026. The filing contains standard certifications and exhibits but the document text provided contains only metadata and filing structure—no financial results, operational updates, product developments, clinical trial data, revenue figures, cash position, or material business changes are included in the excerpt.
Why this rating
Routine quarterly filing; no substantive business data disclosed in excerpt. Cannot assess material events without full financial statements and MD&A.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.